Unicycive Therapeutics, Inc.
UNCY
$6.93
-$0.19-2.67%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 13.61% | -16.02% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -1.61% | 5.44% | |||
| Operating Income | 1.61% | -5.44% | |||
| Income Before Tax | -144.02% | 6.76% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -144.02% | 6.76% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -144.02% | 6.76% | |||
| EBIT | 1.61% | -5.44% | |||
| EBITDA | 1.61% | -5.39% | |||
| EPS Basic | -105.71% | 36.52% | |||
| Normalized Basic EPS | -105.67% | 36.49% | |||
| EPS Diluted | -105.71% | 36.52% | |||
| Normalized Diluted EPS | -105.67% | 36.49% | |||
| Average Basic Shares Outstanding | 18.63% | 46.85% | |||
| Average Diluted Shares Outstanding | 18.63% | 46.85% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||